Amendment to Current Report (Form 8-K/A)

FOR IMMEDIATE RELEASE NEWS RELEASE

Contact:

Robert M. Thornton, Jr.
Chief Executive Officer

(770) 933-7004

SunLink Health Systems, Inc. provides update on Special Cash Dividend

scheduled to be paid prior to

SunLink's proposed merger with Regional Health Properties, Inc.

ATLANTA, Georgia (July 24, 2025) - SunLink Health Systems, Inc. (NYSE American: SSY) today issued the following update with respect to its scheduled $0.10 per share special cash dividend approved by SunLink's Board of Directors and previously announced on July 18, 2025 (the "Special Cash Dividend").

SunLink understands that trades of SunLink common stock entered into during the period (the "due bill period") beginning July 29, 2025 (the record date for the Special Cash Dividend) and through July 30, 2025 (the payment date for the Special Cash Dividend) will have a due bill attached for the Special Cash Dividend. Due bills obligate sellers to deliver the Special Cash Dividend to the buyer. This means that persons who purchase SunLink common stock during the due bill period are entitled to receive the Special Cash Dividend, and persons who sell the stock during the due bill period are not entitled to the Special Cash Dividend. Accordingly, if an investor wishes to receive the Special Cash Dividend, the investor will need to hold the SunLink common stock securities through and including the payment date of July 30, 2025.

The due bill obligations are settled customarily between the brokers representing the buyers and sellers of the securities. Buyers and sellers of SunLink common stock should consult with their broker before trading to ensure they understand the effect of NYSE's due bill procedures. SunLink has no obligations for either the amount of the due bill or the processing of the due bill

SunLink Health Systems, Inc. is the parent company of subsidiaries that own and operate a pharmacy business in the Southeast. For additional information on SunLink Health Systems, Inc., please visit the Company's website.

NO OFFER OR SOLICITATION

Communications in this press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any proxy vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act").

ADDITIONAL INFORMATION

The proposed merger will be submitted to both the Regional and SunLink shareholders for their consideration. In connection with the proposed merger, Regional filed a Registration Statement on Form S-4 (as supplemented or amended, the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") that includes a joint proxy statement/prospectus for Regional and SunLink (the "joint proxy statement/prospectus"), which was sent to common stock shareholders of Regional and common stock shareholders of SunLink on or about June 30, 2025.

INVESTORS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE CORRESPONDING JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED MERGER, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, TOGETHER WITH ALL AMENDMENTS AND SUPPLEMENTS TO THOSE DOCUMENTS, AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.

You are able to obtain a copy of the joint proxy statement/prospectus, as well as other filings containing information about SunLink and Regional, without charge, at the SEC's website (http://www.sec.gov) or by accessing SunLink's website (http://www.sunlinkhealth.com) under the tab "Investors" or by accessing Regional's website (http://www.regionalhealthproperties.com) under the tab "Investor Relations." Copies of the joint proxy statement/prospectus have been mailed to the shareholders of SunLink and Regional who are, as of the respective record dates, entitled to vote on the merger, copies can also be obtained, without charge, by directing a request to Investor Relations, SunLink Health Systems, Inc., 900 Circle 75 Parkway, Suite 690, Atlanta, Georgia, 30339, telephone 770-933-7004 or to Investor Relations, Regional Health Properties, Inc., 1050 Crown Pointe Parkway, Suite 720, Atlanta, Georgia, 30338, telephone 678-869-5116.

SunLink and Regional and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of SunLink and Regional in connection with the proposed merger. Information about the directors and executive officers of SunLink is set forth in Part III of SunLink's Amendment No. 1 to Annual Report on Form 10-K/A for the fiscal year ended June 30, 2024, which information may be updated by SunLink from time to time in subsequent filings with the SEC. Information about the directors and executive officers of Regional is set forth in Part III of Regional's Annual Report on Form 10-K for the year ended December 31, 2024, which information may be updated by Regional from time to time in subsequent filings with the SEC. Additional information about the interests of those participants and other persons who may be deemed participants in the transaction may also

be obtained by reading the joint proxy statement/prospectus relating to the proposed merger. Free copies of this document may be obtained as described above.